TABLE 3.

IgG GMVs against PT, FHA, PRN, and FIM-2 in German trial participants, assorted by vaccine group and analyzed by illness severity

Vaccine groupAntigenGMV, EU/mlP value
Less severe illnessaTypical illnessa
DTPT36.9198.40.002
FHA16.559.90.022
PRN7.112.50.185
FIM-21.21.10.735
DTaPPT49.9157.80.002
FHA126.6199.50.162
PRN186.2358.20.065
FIM-23.24.80.231
DTwPPT62.2100.10.284
FHA17.657.30.029
PRN51.8140.10.037
FIM-27.919.50.080
  • a Typical, see footnote to Table 2 for description of WHO criteria; less severe, ≥7 days of cough, with the same laboratory and household-contact criteria given in the WHO definition. For the DT group, 12 subjects had less severe symptoms and 89 had typical symptoms; for the DTaP vaccine group, 39 subjects had less severe symptoms and 44 had typical symptoms; and for the DTwP group, 30 subjects had less severe symptoms and 18 had typical symptoms.